SynthesisCurrent nutrition reports2025
Antidiabetic Potential of Bananas (Musa spp.): A Systematic Review of Bioactive Compounds and Antihyperglycemic Activities.
Synthesis in Current nutrition reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewBananas (Musa spp.), a staple fruit crop in Southeast Asia, are widely recognised for their nutritional value and potential medicinal properties, including the management of diabetes. To address the diabetes pandemic, various studies have explored the efficacy of many natural foods in reducing blood glucose, preventing complications that arise from the chronic illness. However, a comprehensive overview of bioactive compounds and their antidiabetic effects across different banana species in recent years is lacking. This review provides a comprehensive overview of bioactive compounds in various parts of the bananas that have demonstrated antihyperglycemic activities. Following Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, we conducted a thorough literature search using ScienceDirect, Scopus, and PubMed databases, resulting in the inclusion of 27 relevant articles. RECENT
findingsEmerging evidence suggests that different parts of the banana plant contain various bioactive compounds with antihyperglycemic activities, offering promising benefits for diabetes management. The findings reveal that the antihyperglycemic effects of bananas can be attributed to specific bioactive compounds, such as phenols, saponins, alkaloids, sterols, and flavonoids, through mechanisms like inhibition of α-glucosidase, β-glucosidase, α-amylase and sucrase enzymes, glucose uptake assay, and inhibition of formation of advanced glycation end-products. Liver glycogen content and fasting blood glucose in rat models, along with HbA1c measurements in human subjects, were also assessed to evaluate invivo antidiabetic activity, which has yielded positive outcomes. The results support the potential medicinal and pharmaceutical benefits of bananas in clinical diabetes management and suggest that incorporating banana-derived compounds could enhance the cost-effectiveness of antidiabetic treatments.
Indexed as
Identifiers
40011287What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.